Compare Southwest Airlines Co (LUV) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Southwest Airlines Co vs TG Therapeutics Inc — how do they compare? Southwest Airlines Co trades at $41.66 (market cap $20.23B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Southwest Airlines Co is far larger — about 2.5× TG Therapeutics Inc's market cap, and Southwest Airlines Co pays a 1.74% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Southwest Airlines Co for 65 Days and TG Therapeutics Inc for 16 Days on average.
| LUV | TGTX | |
|---|---|---|
Market Cap | $20.23B | $8.16B |
Volume | 14,560,422 | 1,735,121 |
Sector | Industrials | Health |
52-Week High | $54.80 | $59.06 |
52-Week Low | $29.67 | $26.94 |
Typical Hold Time | 65 Days | 16 Days |
Enterprise Value | $23.33B | $8.37B |
Dividend Yield | 1.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Southwest Airlines (LUV) trades at $41.66, down 0.14% with a bearish technical signal. The stock shows mixed earnings performance with a recent Q2 beat but Q1 miss. Valuation metrics appear reasonable with P/E of 25.85 and P/S of 0.72. The company is undergoing a commercial transformation with new fare structures expected to generate significant EBIT growth, though net margins remain thin at 2.78%. Cash flow trends show improvement projected for 2026 with positive net cash flow of $316M.
LUV presents a turnaround opportunity with its revenue transformation initiatives targeting over $2 billion EBIT in 2026. The 19% upside to consensus price target of $49.61 offers potential reward, but risks include high fuel costs, competitive pressure from legacy carriers, and execution challenges. Analyst sentiment is mixed with 42% buy ratings amid ongoing operational changes.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
